A PILOT CLINICAL-TRIAL OF THE CHOLECYSTOKININ RECEPTOR ANTAGONIST-MK-329 IN PATIENTS WITH ADVANCED PANCREATIC-CANCER

被引：40
作者：
ABBRUZZESE, JL
GHOLSON, CF
DAUGHERTY, K
LARSON, E
DUBROW, R
BERLIN, R
LEVIN, B
机构：
[1] Departments of Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX
[2] Diagnostic Radiology, University of Texas M. D. Anderson Cancer Center, Houston
[3] St. Louis University Hospital, St Louis, MO
[4] Merck, Sharpe, and Dohme Research Laboratories, West Point, PA
来源：
PANCREAS | 1992年 / 7卷 / 02期
关键词：
CHOLECYSTOKININ; MK-329; PANCREATIC CANCER;
D O I：
10.1097/00006676-199203000-00006
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
MK-329 is a nonpeptidal, highly specific cholecystokinin (CCK) receptor antagonist, with affinity for pancreatic and gallbladder CCK receptors similar to CCK itself. MK-329 and its progenitor, asperlicin, can inhibit the growth of CCK receptor-positive human pancreatic cancer in athymic mice. Based on these activities and the ability of MK-329 to transiently increase food intake and enhance morphine analgesia in murine models, we conducted an open trial of MK-329 in 18 patients with advanced pancreatic cancer in whom the CCK receptor status of the tumors was unknown. Tumor response, pain control, and nutritional parameters (hunger rating, caloric intake, body weight, and anthropometrics) were serially assessed. The results of the study failed to demonstrate any impact of MK-329 on tumor progression, pain, or nutrition. Toxicity was mild and limited to nausea, vomiting, diarrhea, and abdominal cramps, with 17 of 18 patients able to tolerate treatment. While a role for MK-329 in the management of patients with advanced pancreatic cancer cannot be supported by the results of this trial, additional studies of this agent in patients with known CCK receptor-positive tumors, at escalated doses, and possibly in conjunction with other growth antagonists, appear warranted.
引用
收藏
页码：165 / 171
页数：7
相关论文
共 34 条
  • [1] Fisher R.J., Bader J.P., Papas T.S., Oncogenes and the mitogenic signal pathway, Important Advances in Oncology, 1989, pp. 3-27, (1989)
  • [2] Spom M.B., Roberts A.B., Peptide growth factors: Current status and therapeutic opportunities, Important Advances in Oncology, 1987, pp. 75-86, (1987)
  • [3] Bogden A.E., Taylor J.E., Kim S.H., Moreau J.P., Coy D.H., Selective in vivo antitumor activity of bombesin/gastric releasing peptide (BN/GRP analogs) [Abstract], Proc Annu Meet am Assoc Cancer Res, 31, (1990)
  • [4] Johnson L.R., New aspects of the trophic action of gastrointestinal hormones, Gastroenterology, 72, pp. 788-792, (1977)
  • [5] Johnson L.R., Effects of gastrointestinal hormones on pancreatic growth, Cancer, 47, pp. 1640-1645, (1981)
  • [6] Dembinski A.B., Johnson L.R., Growth of pancreas and gastrointestinal mucosa in antrectomized and gastrin-treated rats, Endocrinology, 105, pp. 769-773, (1979)
  • [7] Dembinski A.B., Johnson L.R., Stimulation of pancreatic growth by secretin, caerulein, and pentagastrin, Endocrinology, 106, pp. 323-328, (1980)
  • [8] Townsend C.M., Franklin R.B., Watson L.C., Glass E.J., Thompson J.C., Stimulation of pancreatic cancer growth by caerulein and secretin, Surg Forum, 32, pp. 228-229, (1981)
  • [9] Smith J.P., Barrett B., Solomon T.E., CCK stimulates growth of five human pancreatic cancer cell lines in serum-free medium [Abstract], Gastroenterology, 92, (1987)
  • [10] Upp J.R., Singh P., Townsend D.M., Thompson J.C., Thompson P., Predicting response to endocrine therapy in human pancreatic cancer with cholecystokinin receptors [Abstract], Gastroenterology, 92, (1987)
1234